Geriatric Nursing
Volume 26, Issue 2 , Pages 74-78 , March 2005

Dementia treatment update

  • Marti D. Buffum, DNSc, APRN, BC, CS

      Affiliations

    • Marti D. Buffum, DNSc, APRN, BC, CS, Associate chief, Nursing Service for Research, Veterans Affairs Medical Center, San Francisco, and associate clinical professor, University of California School of Nursing, San Francisco
    • ,
  • John C. Buffum, PharmD, BCPP

      Affiliations

    • John C. Buffum, PharmD, BCPP, Associate clinical professor, University of California School of Pharmacy, San Francisco, California.

References 

    References
  1. Hebert LE, Scherr PA, Bienias JL, et al.  Alzheimer disease in the U.S. population: prevalence estimates using the 2000 Census. Arch Neurol. 2003;60:1119–1122
  2. Etminan M, Gill S, Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. BMJ. 2003;327:1–5
  3. Martyn C. Anti-inflammatory drugs and Alzheimer's disease. Evidence implying a protective effect is as yet tentative. BMJ. 2003;327:353–354
  4. Gasparini L, Ongini E, Wenk G. Non-steroidal anti-inflammatory drugs (NSAIDs) in Alzheimer's disease: old and new mechanisms of action. J Neurochem. 2004;91:521–536
  5. Evans JG, Wilcock G, Birks J. Evidence-based pharmacotherapy of Alzheimer's disease. Int J Neuropsychopharmacol. 2004;7:351–369
  6. The Cochrane Database of Systematic Reviews. The Cochrane Library Web site: http://www.cochrane.org. Accessed December 15, 2004.
  7. Cummings JL. Alzheimer's disease. N Engl J Med. 2004;351:56–67
  8. Drugs and therapies. Alzheimer's Association Web site: http://www.alzforum.org/dis/tre/drt/default.asp. Accessed December 17, 2004.
  9. Drugs in clinical trials. Alzheimer's Association Web site: http://www.alzforum.org/dis/tre/drc/. Accessed December 17, 2004.
  10. Forest Laboratories. Package insert. Namenda® (memantine hydrochloride). 2003.
  11. Novartis Pharmaceuticals. Package insert. Exelonreg; (rivastigmine tartrate). 2004.
  12. Areosa Sastre A, McShane R, Sherriff F. Memantine for dementia. The Cochrane Database of Systematic Reviews 2004;4:CD003154.pub2. DOI: 10.1002/14651858.CD 003154.pub2.
  13. Orgogozo J, Rigaud A, Stoffler A, et al.  Efficacy and safety of memantine in patients with mild to moderate vascular dementia. Stroke. 2002;33:1834–1839
  14. Pantoni L. Treatment of vascular dementia: Evidence from trials with non-cholinergic drugs. J Neurol Sci. 2004;226:67–70
  15. Tariot PN, Farlow MR, Grossberg GT, et al.  Memantine Study Group. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil. A randomized controlled trial. JAMA. 2004;291:317–324
  16. AD2000 Collaborative Group . Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomized double-blind trial. Lancet. 2004;363:2105–2115
  17. Schneider LS. Commentary. AD2000: donepezil in Alzheimer's disease. Lancet. 2004;363:2100–2101
  18. Forest Laboratories. FDA accepts supplemental New Drug Application filing to expand Namenda's® indication to include treatment of mild Alzheimer's disease. Press release, November 15, 2004. http://www.frx.com. Accessed January 1, 2005.
  19. Pomara N, Peskind ER, Potkin SG. Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer's disease: A randomized controlled trial [abstract 01-05-04]. Presented at the 9th International Conference on Alzheimer's Disease and Related Disorders, Philadelphia, July 2004.
  20. Tariot PN, Doody R, Peskind E. Memantine treatment for mild to severe Alzheimer's disease: Clinical trials summary [abstract P1-021]. Poster presented at the 9th International Conference on Alzheimer's Disease and Related Disorders, Philadelphia, July 2004.
  21. Semla TP, Beizer JL, Higbee MD. In: Geriatric dosage handbook. 10th ed.. Hudson, OH: Lexi-Comp; 2005;
  22. Cummings JL. Use of cholinesterase inhibitors in clinical practice. Evidence-based recommendations. Am J Geriatr Psychiatry. 2003;11:131–145
  23. Lanctôt KL, Herrmann N, Yau KK, et al.  Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. CMAJ. 2003;169:557–564

☆ Disclosure of potential conflict of interest—M. D. Buffum owns shares of Pfizer. J. C. Buffum owns shares of Neurobiological Technologies, Inc.

PII: S0197-4572(05)00021-2

doi: 10.1016/j.gerinurse.2005.01.003

Geriatric Nursing
Volume 26, Issue 2 , Pages 74-78 , March 2005

Article Tools